| Literature DB >> 31405233 |
Joanna Kwiecińska-Piróg1, Krzysztof Skowron2, Tomasz Bogiel1, Agata Białucha1, Jana Przekwas3, Eugenia Gospodarek-Komkowska1.
Abstract
Vitamin C has antimicrobial activity and is often used as an oral supplement accompanying antibiotic treatment in urinary tract infections (UTI). Proteus mirabilis is the third common species responsible for UTIs that are mostly treated with fluoroquinolones or aminoglycosides. Treatment of the UTI caused by P. mirabilis is problematic due to the ability to form biofilm on the urinary catheters. The aim of the study was to evaluate the influence of ascorbic acid in combination with antibiotics on P. mirabilis abilities to form biofilm. The susceptibility of P. mirabilis reference strain ATCC® 29906™ and four clinical strains isolated from the urine samples of patients with urinary catheter were evaluated according to EUCAST recommendations. The influence of ascorbic acid (0.4 mg × mL-1) in combination with antibiotics on biofilm formation was evaluated spectrophotometrically. Aminoglycosides at sub-inhibitory concentrations more successfully limited biofilm formation by P. mirabilis strains without ascorbic acid addition. Inhibition rate differences at the lowest concentrations of gentamicin and amikacin were statistically significant (p ≤ 0.05). Ascorbic acid addition to the culture medium limited the inhibitory effect of fluoroquinolones, facilitating biofilm formation by P. mirabilis strains. The addition of ascorbic acid during aminoglycosides therapy may disturb treatment of urinary tract infections related to the presence of P. mirabilis biofilm.Entities:
Keywords: Proteus mirabilis; antimicrobial resistant; ascorbic acid; biofilm formation
Year: 2019 PMID: 31405233 PMCID: PMC6783857 DOI: 10.3390/antibiotics8030116
Source DB: PubMed Journal: Antibiotics (Basel) ISSN: 2079-6382
The Minimal Inhibitory Concentration values of the examined antibiotics and ascorbic acid.
| Strain No. | GEN | AMK | CIP | NOR | LEV | AA |
|---|---|---|---|---|---|---|
| S1 | 0.500 | 0.016 | 0.001 | 0.004 | 0.016 | 10.000 |
| S2 | 0.250 | 0.016 | 0.001 | 0.002 | 0.008 | 10.000 |
| S3 | 0.004 | 0.002 | 0.001 | 0.002 | 0.008 | 10.000 |
| S4 | 0.500 | 0.008 | 0.001 | 0.008 | 0.016 | 10.000 |
| R | 0.250 | 0.016 | 0.001 | 0.004 | 0.016 | 10.000 |
GEN—gentamicin, AMK—amikacin, CIP—ciprofloxacin, NOR—norfloxacin, LEV—levofloxacin, AA—ascorbic acid, S1-4—clinical strains, R—reference strain.
Figure 1Absorbance values corresponding to biofilm formation in the presence of ascorbic acid (0.4 mg × mL−1).
Figure 2Biofilm Inhibitory Rate values in the presence of aminoglycosides (a,b,c,…—values marked with different letters differ statistically significant at the significance level p ≤ 0.05).
Figure 3Biofilm Inhibitory Rate values in the presence of fluoroquinolones (a,b,c,…—values marked with different letters differ statistically significant at the significance level p ≤ 0.05).
Proteus mirabilis average Biofilm Inhibition Rate in terms of antibiotic MIC values with (+AA) and without ascorbic acid addition (0.4 mg × mL−1).
| Antibiotic Concentration | Biofilm Inhibition Rate [%] | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aminoglycosides | Fluoroquinolones | ||||||||||||||
| GEN | GEN + AA | AMK | AMK + AA | CIP | CIP + AA | NOR | NOR + AA | LEV | LEV+AA | ||||||
| 0.064 MIC | 14.9 | NS | −94.7 | 56.3 | 0.028 | −63.7 | −20.1 | NS | −9.5 | 77.6 | NS | 68.4 | 39.8 | NS | 40.6 |
| 0.125 MIC | 16.7 | NS | −50.5 | 62.5 | 0.047 | −6.0 | −20.2 | NS | −11.1 | 79.8 | NS | 77.4 | 31.8 | NS | 42.3 |
| 0.25 MIC | 29.3 | NS | 0.7 | 77.6 | 0.016 | 9.5 | −6.6 | NS | −5.8 | 85.4 | 0.047 | 73.1 | 63.4 | NS | 50.5 |
| 0.5 MIC | 54.3 | NS | 5.6 | 89.4 | 0.009 | 8.8 | 20.5 | NS | 7.6 | 90.4 | 0.047 | 75.7 | 58.5 | NS | 48.3 |
| 1 MIC | 87.5 | 0.028 | 41.6 | 89.3 | 0.028 | 54.3 | 53.0 | NS | 32.8 | 92.2 | NS | 91.1 | 83.6 | NS | 66.5 |
GEN—gentamicin, AMK—amikacin, CIP—ciprofloxacin, NOR—norfloxacin, LEV—levofloxacin, * p-value—statistically significant differences in the level of biofilm inhibition depending on the addition of ascorbic acid.
Characteristics of P. mirabilis clinical isolates.
| Strain No | Disease Diagnosis | Sex | Patients Age | Antibiotic Treatment |
|---|---|---|---|---|
| S1 | UTI | Female | 85 Years | Amoxicillin/clavulanic acid |
| S2 | Abdominal hernia surgery | Female | 59 Years | None |
| S3 | UTI (urinary stones) | Female | 86 Years | Ciprofloxacin |
| S4 | UTI | Male | 18 Months | None |
UTI—Urinary Tract Infection.